SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Tonix Pharmaceuticals To Report Results From Preclinical Study Of TNX-1900 Will Be Presented At AAN Sports Concussion Virtual Conference

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900

Benzinga · -

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology's first-ever Sports Concussion Conference. The research was sponsored by Trigemina, Inc. and in June Tonix acquired the assets of Trigemina including certain rights to the data described on the poster. Dr. Shashidhar Kori was formerly chief medical officer of Trigemina. Dr. David Yeomans and Dr. Michael Klukinov are on the faculty of Stanford University. Dr. Kori and Dr. Yeomans are currently consultants to Tonix. The virtual meeting is being held July 31 and August 1, 2020.
 

Details of the poster presentation:

Title: Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)

Authors: Shashidhar H Kori, David Yeomans, Michael Klukinov

Date and Time: The 2020 Sports Concussion Virtual Conference poster presentations will be available starting at 4:00 p.m. ET, Friday, July 31, 2020